

Carmela Coppola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8590724/publications.pdf>

Version: 2024-02-01

30
papers

1,305
citations

279798

23
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

2045
citing authors

#	ARTICLE	IF	CITATIONS
1	The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity. <i>Cancers</i> , 2020, 12, 235.	3.7	39
2	Management of QT Prolongation Induced by Anticancer Drugs. <i>Current Clinical Pathology</i> , 2019, , 123-132.	0.0	0
3	Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs. <i>Cancer Treatment Reviews</i> , 2018, 63, 135-143.	7.7	56
4	Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity. <i>Nutrients</i> , 2018, 10, 1304.	4.1	62
5	Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production. <i>Frontiers in Physiology</i> , 2018, 9, 38.	2.8	36
6	Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2241-2250.	2.0	26
7	Intracardiac metastasis originated from chondrosarcoma. <i>Journal of Cardiovascular Medicine</i> , 2017, 18, 385-388.	1.5	4
8	Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6785-6794.	2.0	24
9	Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e55-e63.	1.5	12
10	Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, e19-e26.	1.5	47
11	Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1124-1131.	3.3	46
12	Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype. <i>Diabetology and Metabolic Syndrome</i> , 2014, 6, 105.	2.7	17
13	Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. <i>European Journal of Heart Failure</i> , 2014, 16, 358-366.	7.1	76
14	Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 83-88.	2.1	16
15	The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. <i>European Journal of Heart Failure</i> , 2013, 15, 482-489.	7.1	61
16	Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. <i>European Journal of Heart Failure</i> , 2012, 14, 130-137.	7.1	77
17	Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 511-521.	2.5	43
18	Le alterazioni elettrocardiografiche espressione di cardiotossicit�. <i>Journal of Cardiovascular Echography</i> , 2011, 21, 55-59.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Early Identification of Left Ventricular Dysfunction Induced by Trastuzumab. Journal of the American College of Cardiology, 2011, 58, 2698-2699.	2.8	3
20	Women survive breast cancer but fall victim to heart failure: the shadows and lights of targeted therapy. Journal of Cardiovascular Medicine, 2010, 11, 861-868.	1.5	45
21	Fludarabine prevents smooth muscle proliferation in vitro and neointimal hyperplasia in vivo through specific inhibition of STAT-1 activation. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2935-H2943.	3.2	61
22	Aging exacerbates negative remodeling and impairs endothelial regeneration after balloon injury. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H2850-H2860.	3.2	53
23	Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H902-H908.	3.2	35
24	Physical Training Increases eNOS Vascular Expression and Activity and Reduces Restenosis After Balloon Angioplasty or Arterial Stenting in Rats. Circulation Research, 2002, 91, 1190-1197.	4.5	85
25	Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21rasActivation. Circulation, 2002, 106, 2118-2124.	1.6	105
26	Rat carotid artery dilation by PTCA balloon catheter induces neointima formation in presence of IEL rupture. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H760-H767.	3.2	46
27	Membrane-Bound Protein Kinase A Inhibits Smooth Muscle Cell Proliferation In Vitro and In Vivo by Amplifying cAMP-Protein Kinase A Signals. Circulation Research, 2001, 88, 319-324.	4.5	45
28	Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Islet-Transplanted Rats. Circulation, 2001, 103, 2980-2986.	1.6	104
29	A new rat model of small vessel stenting. Basic Research in Cardiology, 2000, 95, 179-185.	5.9	43
30	Gene Therapy for Restenosis after Balloon Angioplasty and Stenting. Cardiology in Review, 1999, 7, 324-331.	1.4	38